
    
      This clinical trial is a prospective, single-organ, phase II clinical trial to evaluate the
      efficacy of curative proton therapy for pulmonary metastasis of colon cancer diagnosed
      histologically as adenocarcinoma.

      Patients who meet the selection criteria should be selected, signed for consent, and treated
      5 times a week for 7200 cGy / 15 fractions alone for 3 weeks.
    
  